Dr. Vuong Trieu, Developer of Novel Oncology and Immunotherapy Assets, Leads Oncotelic Therapeutics' Commitment to Innovation, Life-Saving Therapies

Core Insights - Oncotelic Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative oncology and immunotherapy treatments, with a strong emphasis on addressing high unmet medical needs in cancer and rare pediatric diseases [1][5] Company Overview - The company is led by Dr. Vuong Trieu, who has a significant impact on the biopharma industry through his extensive intellectual property portfolio, including over 500 filed patents and 75 issued patents [2][4] - Oncotelic's strategy involves building value through differentiated biotechnology assets that create strong competitive barriers [4][6] Clinical Pipeline - Oncotelic's clinical pipeline includes several key drug candidates: - OT-101 (TGF-β inhibitor): Currently in Phase 3 for pancreatic cancer, with potential applications in ARDS/COVID-19 [7] - OXi4503 (vascular disrupting agent): In Phase 2 for AML/MDS, moving towards pivotal Phase 3 design [7] - CA4P / Fosbretabulin: A late-stage oncology asset undergoing repositioning [7] - AL-101 (intranasal apomorphine): In Phase 2 for Parkinson's disease and sexual dysfunctions [7] - AL-102 (oligonucleotide antisense via intrathecal injection): In discovery stage for Alzheimer's disease [7] - Pediatric Rare Disease Programs: Targeting orphan indications with potential for Priority Review Vouchers (PRVs) [7] Intellectual Property and Collaborations - The company benefits from Dr. Trieu's inventions, which form the cornerstone of its intellectual property portfolio, enhancing its strategic position in oncology and rare disease therapeutics [4][6] - Oncotelic also engages in licensing and co-developing select drug candidates through joint ventures, including a 45% ownership in GMP Bio, which is advancing its own pipeline [6]